{"version":"1.0","provider_name":"The Medical Xchange","provider_url":"https:\/\/themedicalxchange.com\/en\/","title":"Emerging Outcomes Data with PCSK9 Inhibitors Show Cardiovascular Risk Reductions in Line with LDL Control - The Medical Xchange","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"Qc51KCoJuh\"><a href=\"https:\/\/themedicalxchange.com\/en\/2015\/03\/23\/american-college-of-cardiology-64th-annual-scienti\/\">Emerging Outcomes Data with PCSK9 Inhibitors  Show Cardiovascular Risk Reductions in Line with LDL Control<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/themedicalxchange.com\/en\/2015\/03\/23\/american-college-of-cardiology-64th-annual-scienti\/embed\/#?secret=Qc51KCoJuh\" width=\"600\" height=\"338\" title=\"&#8220;Emerging Outcomes Data with PCSK9 Inhibitors  Show Cardiovascular Risk Reductions in Line with LDL Control&#8221; &#8212; The Medical Xchange\" data-secret=\"Qc51KCoJuh\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script type=\"text\/javascript\">\n\/* <![CDATA[ *\/\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/\/# sourceURL=https:\/\/themedicalxchange.com\/wp-includes\/js\/wp-embed.min.js\n\/* ]]> *\/\n<\/script>\n","thumbnail_url":"https:\/\/themedicalxchange.com\/wp-content\/uploads\/2015\/03\/2348_ACC_2015_EN_Fig1.PNG","thumbnail_width":960,"thumbnail_height":720,"description":"San Diego \u2013 The same relationship between lipid lowering and cardiovascular risk reductions established with statins is being seen with the novel PCSK9 inhibitors, according to data presented at the annual meeting of the ACC. The findings, although preliminary, provide promise for the large proportion of high-risk patients who are not reaching treatment goals on statins alone or who are intolerant to statins. So far, safety data in the large trial programs with the PCSK9 inhibitors have yet to identify any major adverse events."}